Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (26715)	12/1/1998 3:15:00 AM
From: Henry Niman	Respond to of 32384

Bob, Since the advisory committee met only 9 days prior to the 6 month deadline, it's not surprising that a few details remain. I'm not surprised that LGND has already submitted the chemistry detail. I suspect that the data was readily available and was submitted in response to FDA requests. As far as the labeling is concerned, I don't think that much could have been done before te meeting, because no one really knew for certain what the committee would suggest. After the meeting, it was possible to negotiate the labeling. LGND has a sales force ready to go, so I suspect that the labeling issues will be resolved very quickly and a launch this year is very possible (although the launch this will probably be hampered by the holidays, as suggested many weeks ago by on of the analysts (Bear Stearns?).

To: Machaon who wrote (26715)	12/1/1998 8:37:00 AM
From: Henry Niman	Respond to of 32384

LGND is holding a conference call at 800.659.4363 Bear Stearns has issued a reiterated BUY this morning David Robinson is talking and reviewing the press release. Work required by FDA is "doable this year".

To: Machaon who wrote (26715)	12/1/1998 9:24:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Conference call was very upbeat on near term approval. Chemistry issue relates to expiration date. Different FDA sections review the application, and its hard for them all to meet the 6 month deadline. The marketing force is in place and has been building a contact base for the past 60 days. The compound can be supplied within days of approval (unless packaging insert needs to be tweaked, which could take a few more days). The "at risk" material has also been printed. There are 20 sales reps in the US and 18 of the 20 territories have been filled. They are currently targeting 150 centers. Next year the # of territories is expected to expand to 26. In addition there are 4 regional managers and 3 accountants. Since Panretin is an orphan drug, it will enjoy the associated reimbursement privleges. Some distribution may require 30-90 days to get through buyers. Systemic treatments currently cost between $8,500 and $12,000 per course. Panretin will be less (in the $5,000 to $7,000 range) and exact pricing will depend on dose, duration, and continue to treat recommendations. Qustions were asked by BBRS (Mike King) and Farallon (David ?). US KS population estimated to be about 12,000 (between 9,000 and 15,000). New KS patients declined by over 50%, but not due to anti-retroviral therapy (decline began before new drugs were introduced). In the past, patient dies 12-14 months after diagnosed with KS. Now patients lives 3-5 years or more. KS not being cured by HAART therapy. 80% of patients in Panretin trial had been on HAART for some time. Chemo also not curing disease. Panretin redness and pain only for initial treatments. Western Europe more robust. NAA filing in Jan'Feb anticipated, but going through reimbursement procedure takes longer there. Estimate 15,000 to 20,000 patients in EEC. Classical KS also responds to Panretin. US patient population in the 1,000 to 2,000 range. Panretin also can be use to treat problems associated with opportunistic infections in transplant patients. Off label uses include Muluscum Contagious (in HIV and non-HIV patients) as well as conoulomata (sp?) patients. LGND plans to start testing next year in basal and squamous cell carcinoimas as well as safety trials using Panretin with systemic treatment of KS.